Posterior chamber collagen copolymer phakic intraocular lenses to correct myopia: Five-year follow-up
Posterior chamber collagen copolymer phakic intraocular lenses to correct myopia: Five-year follow-up
复制标题
DOI：
10.1016/j.jcrs.2010.11.040
复制
发表时间：
2011-05-01
影响因子：
2.8
通讯作者：
Montes-Mico, Robert
中科院分区：
文献类型：
--
作者：
Alfonso, Jose F.;Baamonde, Begona;Montes-Mico, Robert
目的：评价后房型共聚物晶状体人工晶状体植入术矫正近视的长期安全性和有效性。地点：西班牙奥维耶多Fernandez-Vega眼科研究所。设计：队列研究。方法：对中度至高度近视患者植入Visian植入式collamer Lens pIOL后5年的未矫正（UDVA）和矫正（CDVA）距离视力、屈光、pIOL拱顶、内皮细胞损失和不良事件进行评估。结果：平均球等效度（188眼）由术前-11.17 (D) +/- 3.40 （SD）降至术后5年-0.88 +/- 0.72 D。1个月至5年的平均折射变化为-65 +/- 0.65 d，平均UDVA和CDVA （Snellen十进制）分别为0.69 +/- 0.26和0.83 +/- 0.15。平均安全性和有效性指数分别为1.27 +/- 0.33和0.89 +/- 0.35。视力损失不超过2线；70%达到0.80或更高的CDVA。3只眼（1.6%）出现晚期前囊下白内障，1例临床表现明显，导致pIOL摘除和超声乳化手术。3只眼（1.6%）出现短暂性眼压轻度升高（高达27毫米汞柱），没有人需要第二次手术或长期局部用药。总内皮细胞损失（连续5年累积考虑）为7.7%。随着时间的推移，pIOL拱顶有降低的趋势。无危及视力的并发症发生。结论：胶原共聚物pIOL植入术治疗中高度数近视安全有效，屈光效果长期稳定，可预测。
PURPOSE: To evaluate the long-term safety and efficacy of posterior chamber collagen copolymer phakic intraocular lens (pIOL) implantation to correct myopia.SETTING: Fernandez-Vega Ophthalmological Institute, Oviedo, Spain.DESIGN: Cohort study.METHODS: Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, pIOL vault, endothelial cell loss, and adverse events were evaluated for 5 years after implantation of the Visian Implantable Col lamer Lens pIOL for moderate to high myopia.RESULTS: The mean spherical equivalent (188 eyes) decreased from -11.17 diopters (D) +/- 3.40 (SD) preoperatively to -0.88 +/- 0.72 D 5 years postoperatively. The mean change in refraction from 1 month to 5 years was -65 +/- 0.65 D. The mean UDVA and CDVA (Snellen decimal) were 0.69 +/- 0.26 and 0.83 +/- 0.15, respectively. The mean safety and efficacy indices were 1.27 +/- 0.33 and 0.89 +/- 0.35, respectively. No eye lost more than 2 lines of visual acuity; 70% achieved 0.80 or better CDVA. Three eyes (1.6%) developed late anterior subcapsular cataract that was clinically significant in 1 case, leading to pIOL removal and phacoemulsification. Of the 3 eyes (1.6%) with a mild transient increase in intraocular pressure (up to 27 mm Hg), none required a second surgical procedure or prolonged topical medication. The total endothelial cell loss (considered cumulatively at consecutive intervals through 5 years) was 7.7%. There was a tendency toward decreased pIOL vault decrease over time. No vision-threatening complications occurred.CONCLUSION: Implantation of the collagen copolymer pIOL for moderate to high myopia was safe and effective and provided long-term predictable, stable refractive results.